BMY.US Weekly Report · 2026-W29
BMY closed at $60.74 this week, up 0.38%. The stock showed modest performance with moderate trading activity. The most noteworthy development is the extremely low valuation—P/E at just 17.05, placing it at the 3.56th percentile over the past five years—which contrasts sharply with a relatively optimistic analyst rating distribution. Capital flows, however, reveal disagreement: while large players are withdrawing, medium-sized and retail investors are buying, signaling divergent market expectations.
Price Action and Volume
During the week of July 13-17, 2026, BMY closed at $60.74, up 0.38% from the prior week’s close of $60.51. The weekly range was 2.99% (high: $62.29, low: $60.47), with price consolidation in a narrow band.
Weekly volume reached 12.26 million shares with aggregate turnover of $750.21 million. Compared to the 60-day median volume of approximately 11 million shares, this week saw modest volume expansion. The turnover rate stood at 0.6%, within normal ranges.
Daily price action showed a gap-up open Monday (July 13) at $59.34, followed by a sharp decline to $56.95 on Tuesday, a recovery to $58.72 on Wednesday, and a strong rally to $60.51 on Thursday. Friday’s attempted surge to $62.29 failed to sustain, closing at $60.74. The pattern reflects “lower open, sharp dip, recovery, failed breakout”—accumulation dynamics with persistent selling pressure.
Valuation and Earnings
As of July 17, 2026, BMY’s P/E ratio stood at 17.05x with a P/B ratio of 6.18x. In historical context, the current P/E is at the 3.56th percentile over the past five years, meaning approximately 96% of trading days in the past five years saw higher P/E multiples. This represents an extremely depressed valuation level, well below industry medians.
The dividend yield (DPS rate) is 4.13%, providing reasonable income appeal. Market capitalization stands at approximately $124 billion.
Consensus earnings expectations show stable conditions: 2026 EPS consensus mean of $6.12 with a median of $6.16, ranging from $5.43 to $6.66 across 47 contributing institutions. Recent weekly snapshots show no material changes in estimates, with no coordinated upward or downward revisions observed.
Capital Flows and Institutional Views
Capital flows display clear divergence. Large investors (major blocks) recorded net outflows of approximately $919.72 million (inflows $756.26M, outflows $1,675.98M). Medium-sized investors showed net inflows of roughly $174.04 million, and retail capital net inflows of approximately $144.63 million. This divergence suggests disagreement among market participants about the stock’s direction.
The institutional rating consensus is “Hold.” Distribution: 6 Buy, 17 Hold, 4 Underperform, 1 Sell, across 29 total ratings. Within the pharmaceutical sector’s 255 comparable companies, BMY ranks 29th in valuation (middle-upper tier). Price targets range from $40 to $75 with a mean of $62.96, implying 3.7% upside from current levels.
Note that ratings updated as of July 17 carry inherent lag; they may not yet reflect this week’s rapid shifts in capital flows.
This Week’s News
Key BMY-related developments during the week:
-
FDA accepts Bristol-Myers NDA for mezigdomide in multiple myeloma, sets May 13, 2027 decision date —— A new treatment option for multiple myeloma with standard 12-month review timeline.
-
Bristol-Myers Squibb (BMY) Receives a Hold from Citi —— Major institution maintains cautious stance with no upside guidance.
-
Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo —— Reinforces institutional conservatism.
-
Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.12% on Jul 15: Key Drivers Unveiled —— Mid-week rebound that failed to persist.
-
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.99% on Jul 14: Drivers Behind the Movement —— Early-week pullback.
-
Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.07% on Jul 13: Key Drivers Unveiled —— Week open rally.
-
Bristol Myers Squibb on Pace for Largest Percent Decrease Since November 2025 — Data Talk —— Risk alert narrative.
-
10:31 ET Metastatic Castration-resistant Prostate Cancer Market Poised for Strong Growth by 2036 —— Industry tailwind supporting BMY’s oncology portfolio.
-
Top Pharmaceutical Stocks To Watch Now - July 17th —— BMY included in sector watchlist.
-
Bristol-Myers Squibb’s Q2 2026 Earnings: What to Expect —— Pre-earnings preview.
The narrative arc centers on: (1) pipeline progress (mezigdomide FDA acceptance), (2) broad institutional caution (Hold ratings), and (3) price volatility without clear directional catalysts this week.
Summary
BMY presents a classic “extreme valuation discount, fragmented capital flows, institutional hold pattern” setup. P/E at 17.05 sits in the 3.56th historical percentile, theoretically attractive, yet large player withdrawals and predominantly Hold ratings reveal unresolved market consensus. Mezigdomide’s FDA acceptance marks clinical progress but insufficient to shift near-term sentiment. The stock may remain range-bound between $60-62 until next catalyst emerges—whether Q2 earnings, clinical data, or capital flow reversal.
Key monitoring points: (1) Q2 earnings realization versus guidance, (2) whether capital flows reverse at these valuations, (3) whether analyst ratings shift higher given depressed multiples.